Home › Bioprognos Gets CE Mark for Lung Cancer Dx Algorithm

Bioprognos Gets CE Mark for Lung Cancer Dx Algorithm

Dec 20, 2016

NEW YORK (360Dx) – Spanish diagnostics firm Bioprognos announced yesterday that it has received CE marking for MBDAA for Lung Neoplasia Dx — an algorithm used in the diagnosis of lung cancer — clearing it for sale in the European Union.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Aug
27
Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

What's Popular?

In Cancer

  1. China FDA Approves Novogene CDx Test for NSCLC Therapies

  2. Natera Partners With Fox Chase to Evaluate ctDNA Cancer Assay

  3. Genetic Technologies Announces Planned Chinese Joint Venture

  4. MDxHealth Hopes to Build Lead in Prostate Risk Testing With Utility Evidence for SelectMDx

    Premium

  5. GeneNews Posts 88 Percent Decline in Q2 Revenues; Inks Liquid Biopsy Alliance With LifeX

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.